Date

April 9, 2024

Share this News Post

Study Led by Johns Hopkins Medicine Finds Injectable Drug Used to Treat Asthma and Other Allergic Conditions May Limit Reactions in People with Multiple Food Allergies

A study led by Johns Hopkins Children’s Center shows omalizumab — an injectable, Food and Drug Administration (FDA)-approved medication for treating asthma and other allergic conditions — substantially reduced potentially life-threatening reactions in patients with an allergy to peanut and other common food allergies. 

  

A report on the first stage of a three-stage study, which was funded by the National Institutes of Health (NIH), was published on February 25 in The New England Journal of Medicine and presented during a late breaking symposium at the American Academy of Allergy, Asthma & Immunology annual meeting in Washington, D.C. The FDA recently approved omalizumab for treatment of multiple food allergies following an interim analysis based on this study. 

  

In the study, investigators compared the effects of 16–20 weeks of omalizumab injections with placebo injections in 180 participants ranging from age 1 to 55 with a history of peanut allergy and at least two other food allergies. The subjects were randomly assigned to receive omalizumab or placebo. All but three of the participants were age 17 or younger... 

 

Read the full article here.

2023 CTSA Fall Program Annual Meeting Poster Spotlight: Sarah Walker, M.D.

Previous

Barbara Slusher, M.D., M.A.S. Developing Treatment for Inflammatory Bowel Disease

Next